TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for high-risk and advanced cancers, announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately. Fitzgerald, who has served as CFO since July 2018 and also served as a director, will continue to provide transition services to ensure a smooth handover. The company has appointed John Tattory as interim CFO, also effective immediately.
Tattory brings more than 25 years of financial and operational management experience across the pharmaceutical, medical device, and biotechnology sectors. His career includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, he serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies. His extensive background in life sciences finance is expected to be instrumental as TransCode continues to advance its clinical programs.
The leadership change comes at a critical time for TransCode Therapeutics. The company is focused on developing innovative treatments for metastatic cancers, with its lead therapeutic candidate, TTX-MC138, targeting tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. Additionally, TransCode has a portfolio of other first-in-class candidates designed to mobilize the immune system to recognize and destroy cancer cells. The appointment of Tattory as interim CFO ensures financial continuity as the company navigates the complex regulatory and financial landscape of clinical-stage oncology research.
Investors and stakeholders can view the full press release at https://nnw.fm/8G3ik. For ongoing news and updates about TransCode Therapeutics, the company's newsroom is available at https://nnw.fm/RNAZ. NetworkNewsWire, a specialized communications platform, distributes financial news and content for private and public companies. More information about NetworkNewsWire can be found at https://www.NetworkNewsWire.com.
The transition in financial leadership may be seen as a strategic move to bolster TransCode's financial operations as it pursues breakthrough cancer therapies. Tattory's experience with both large pharmaceutical firms and smaller biotech companies could provide valuable insights as TransCode seeks to advance its pipeline and potentially secure additional funding. The company's focus on RNA therapeutics and immuno-oncology places it at the forefront of innovative cancer treatment approaches, and strong financial stewardship will be crucial for successful clinical development and eventual commercialization.
